NCT03850873: A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients treated with other CDK4/6 inhibitors; Patients with brain metastasis- see trial for details

Comments are closed.

Up ↑